{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:47:02Z","timestamp":1784209622559,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,5,16]],"date-time":"2011-05-16T00:00:00Z","timestamp":1305504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,5,16]],"date-time":"2011-05-16T00:00:00Z","timestamp":1305504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1038\/bmt.2011.109","type":"journal-article","created":{"date-parts":[[2011,5,16]],"date-time":"2011-05-16T10:46:37Z","timestamp":1305542797000},"page":"488-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation"],"prefix":"10.1038","volume":"47","author":[{"given":"J","family":"Waterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Rybicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Bolwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Copelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Pohlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Sweetenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Sobecks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,16]]},"reference":[{"key":"BFbmt2011109_CR1","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","volume":"21","author":"JO Armitage","year":"2003","unstructured":"Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S . Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897\u2013906.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011109_CR2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1200\/JCO.2000.18.5.947","volume":"18","author":"IN Micallef","year":"2000","unstructured":"Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947\u2013955.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011109_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0145-2126(00)00092-8","volume":"25","author":"E Misgeld","year":"2001","unstructured":"Misgeld E, Germing U, Aul C, Gattermann N . Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma. Leuk Res 2001; 25: 95\u201398.","journal-title":"Leuk Res"},{"key":"BFbmt2011109_CR4","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1200\/JCO.2002.08.128","volume":"20","author":"VA Morrison","year":"2002","unstructured":"Morrison VA, Rai KR, Peterson BL, Kolitz JE, Appelbaum FR, Hines JD et al. Therapy-related myeloid leukemia's are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002; 20: 3878\u20133884.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011109_CR5","first-page":"1546","volume":"91","author":"CS Tam","year":"2006","unstructured":"Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006; 91: 1546\u20131550.","journal-title":"Haematologica"},{"key":"BFbmt2011109_CR6","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","volume":"22","author":"PL Zinzani","year":"2004","unstructured":"Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654\u20132661.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011109_CR7","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","volume":"14","author":"P McLaughlin","year":"1996","unstructured":"McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262\u20131268.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011109_CR8","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","volume":"27","author":"JW Friedberg","year":"2009","unstructured":"Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27: 1202\u20131208.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011109_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1046\/j.1365-2141.1999.01379.x","volume":"105","author":"G Visani","year":"1999","unstructured":"Visani G, Lemoli RM, Tosi P, Martinelli G, Testoni N, Ricci P et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukemia patients. Br J Haematol 1999; 105: 775\u2013779.","journal-title":"Br J Haematol"},{"key":"BFbmt2011109_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/blood-2003-05-1449","volume":"103","author":"O Tournilhac","year":"2004","unstructured":"Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363\u2013365.","journal-title":"Blood"},{"key":"BFbmt2011109_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bmt.1703525","volume":"29","author":"B Bolwell","year":"2002","unstructured":"Bolwell B, Kalaycio M, Sobecks R, Andresen S, Mcbee M, Kuczkowski L et al. Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up. Bone Marrow Transplant 2002; 29: 673\u2013679.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011109_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11901-005-0025-1","volume":"4","author":"DG Maloney","year":"2005","unstructured":"Maloney DG . Treatment of follicular non-Hodgkin's lymphoma. Curr Hematol Rep 2005; 4: 39\u201345.","journal-title":"Curr Hematol Rep"},{"key":"BFbmt2011109_CR13","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1200\/JCO.2006.06.0673","volume":"24","author":"M Kalaycio","year":"2006","unstructured":"Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 2006; 24: 3604\u20133610.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011109_CR14","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361\u20131392.","journal-title":"Blood"},{"key":"BFbmt2011109_CR15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/sj.bmt.1702433","volume":"25","author":"EA Copelan","year":"2000","unstructured":"Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 25: 1243\u20131248.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011109_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/sj.bmt.1701100","volume":"21","author":"BJ Bolwell","year":"1998","unstructured":"Bolwell BJ, Pohlman B, Andresen S, Kalaycio M, Goormastic M, Wise K et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998; 21: 369\u2013373.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2011109_CR17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","volume":"103","author":"JM Bennett","year":"1985","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute leukemia. Ann Intern Med 1985; 103: 620\u2013629.","journal-title":"Ann Intern Med"},{"key":"BFbmt2011109_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1054\/bjoc.2000.1196","volume":"83","author":"R Saso","year":"2000","unstructured":"Saso R, Kulkarni S, Mitchell P, Treleaven J, Swansbury GJ, Mehta J et al. Secondary myelodysplastic syndrome\/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 2000; 83: 91\u201394.","journal-title":"Br J Cancer"},{"key":"BFbmt2011109_CR19","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/sj.leu.2403326","volume":"18","author":"SJ Morgan","year":"2004","unstructured":"Morgan SJ, Seymour JF, Grigg A, Matthews JP, Prince HM, Wolf MM et al. Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukemia 2004; 18: 1034\u20131038.","journal-title":"Leukemia"},{"key":"BFbmt2011109_CR20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3324\/haematol.12120","volume":"93","author":"S Sacchi","year":"2008","unstructured":"Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Gobbi PG et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93: 398\u2013404.","journal-title":"Haematologica"},{"key":"BFbmt2011109_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1399-0012.2007.00768.x","volume":"22","author":"L Laurenti","year":"2008","unstructured":"Laurenti L, Tarnani M, Chiusolo P, La Torre G, Garzia M, Zollino M et al. Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy. Clin Transplant 2008; 22: 191\u2013199.","journal-title":"Clin Transplant"},{"key":"BFbmt2011109_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1365-2141.2006.06158.x","volume":"134","author":"SJ Bowcock","year":"2006","unstructured":"Bowcock SJ, Rassam SM, Lim Z, Ward SM, Ryali MM, Mufti GJ . High incidence of therapy-related myelodysplasia and acute leukemia in general hematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders. Br J Haematol 2006; 134: 242\u2013243.","journal-title":"Br J Haematol"},{"key":"BFbmt2011109_CR23","first-page":"3580","volume":"7","author":"T Yamauchi","year":"2001","unstructured":"Yamauchi T, Nowak BJ, Keating MJ, Plunkett W . DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 3580\u20133589.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2011109_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood.V100.1.334","volume":"100","author":"G Eissner","year":"2002","unstructured":"Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002; 100: 334\u2013340.","journal-title":"Blood"},{"key":"BFbmt2011109_CR25","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1038\/leu.2008.167","volume":"22","author":"MG Berger","year":"2008","unstructured":"Berger MG, Berger J, Richard C, Jeanpierre S, Nicolini FE, Tournilhac O et al. Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization. Leukemia 2008; 22: 2131\u20132134.","journal-title":"Leukemia"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2011109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011109","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T13:17:48Z","timestamp":1648041468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2011109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,16]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["BFbmt2011109"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2011.109","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,16]]},"assertion":[{"value":"11 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}